论文部分内容阅读
:〔目的〕观察含诺维本的联合化疗方案治疗晚期乳腺癌的疗效和毒副反应。〔方法〕采用NA(E)或NP方案治疗晚期乳腺癌34例。〔结果〕总有效率为588%(20/34),CR147%(5/34),中位生存期14个月。其中初治者有效率为778%(7/9),复治者有效率为520%(13/25)。复治者中14例阿霉素耐药者用NP方案治疗有效率为429%(6/14)。主要毒副作用为骨髓抑制、局部静脉炎、恶心、呕吐。〔结论〕含诺维本联合化疗方案治疗初、复治晚期乳腺癌有效率高,毒副作用可耐受,可作为晚期乳腺癌二线化疗方案。
: [Objective] To observe the curative effect and toxicity of Novubiben combined chemotherapy in the treatment of advanced breast cancer. 〔Methods〕 NA (E) or NP regimen in the treatment of advanced breast cancer in 34 cases. 〔Results〕 The total effective rate was 588% (20/34), CR147% (5/34), the median survival of 14 months. Among them, the effective rate was 778% (7/9) in primary treatment and 520% (13/25) in primary treatment. Forty cases of doxorubicin-resistant patients treated with NP regimen were 429% (6/14) effective. The main side effects of bone marrow suppression, local phlebitis, nausea, vomiting. [Conclusion] Combination of Novobin chemotherapy with early treatment, advanced treatment of advanced breast cancer effective, toxic side effects can be tolerated, can be used as a second-line chemotherapy for advanced breast cancer.